Healio (7/13, Oldt) reports that in a 418-patient, “double-blind, placebo-controlled, randomized” phase 3 study, “lisdexamfetamine dimesylate reduced risk for relapse in moderate to severe binge-eating disorder over six months.” The findings were published online July 12 in JAMA Psychiatry. Psychiatric News (7/12) also covered the study.
Related Links:
— “Lisdexamfetamine dimesylate lowers binge-eating disorder relapse risk,” Hudson JI, et al., Healio, July 13, 2017.